Cargando…

Hypertrophic Cardiomyopathy—Past, Present and Future

Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiomyopathy with a prevalence of 1 in 500 in the general population. Since the first pathological case series at post mortem in 1957, we have come a long way in its understanding, diagnosis and management. Here, we will describe the his...

Descripción completa

Detalles Bibliográficos
Autores principales: Liew, Alphonsus C., Vassiliou, Vassilios S., Cooper, Robert, Raphael, Claire E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5742807/
https://www.ncbi.nlm.nih.gov/pubmed/29231893
http://dx.doi.org/10.3390/jcm6120118
_version_ 1783288456830517248
author Liew, Alphonsus C.
Vassiliou, Vassilios S.
Cooper, Robert
Raphael, Claire E.
author_facet Liew, Alphonsus C.
Vassiliou, Vassilios S.
Cooper, Robert
Raphael, Claire E.
author_sort Liew, Alphonsus C.
collection PubMed
description Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiomyopathy with a prevalence of 1 in 500 in the general population. Since the first pathological case series at post mortem in 1957, we have come a long way in its understanding, diagnosis and management. Here, we will describe the history of our understanding of HCM including the initial disease findings, diagnostic methods and treatment options. We will review the current guidelines for the diagnosis and management of HCM, current gaps in the evidence base and discuss the new and promising developments in this field.
format Online
Article
Text
id pubmed-5742807
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-57428072017-12-29 Hypertrophic Cardiomyopathy—Past, Present and Future Liew, Alphonsus C. Vassiliou, Vassilios S. Cooper, Robert Raphael, Claire E. J Clin Med Review Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiomyopathy with a prevalence of 1 in 500 in the general population. Since the first pathological case series at post mortem in 1957, we have come a long way in its understanding, diagnosis and management. Here, we will describe the history of our understanding of HCM including the initial disease findings, diagnostic methods and treatment options. We will review the current guidelines for the diagnosis and management of HCM, current gaps in the evidence base and discuss the new and promising developments in this field. MDPI 2017-12-12 /pmc/articles/PMC5742807/ /pubmed/29231893 http://dx.doi.org/10.3390/jcm6120118 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Liew, Alphonsus C.
Vassiliou, Vassilios S.
Cooper, Robert
Raphael, Claire E.
Hypertrophic Cardiomyopathy—Past, Present and Future
title Hypertrophic Cardiomyopathy—Past, Present and Future
title_full Hypertrophic Cardiomyopathy—Past, Present and Future
title_fullStr Hypertrophic Cardiomyopathy—Past, Present and Future
title_full_unstemmed Hypertrophic Cardiomyopathy—Past, Present and Future
title_short Hypertrophic Cardiomyopathy—Past, Present and Future
title_sort hypertrophic cardiomyopathy—past, present and future
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5742807/
https://www.ncbi.nlm.nih.gov/pubmed/29231893
http://dx.doi.org/10.3390/jcm6120118
work_keys_str_mv AT liewalphonsusc hypertrophiccardiomyopathypastpresentandfuture
AT vassiliouvassilioss hypertrophiccardiomyopathypastpresentandfuture
AT cooperrobert hypertrophiccardiomyopathypastpresentandfuture
AT raphaelclairee hypertrophiccardiomyopathypastpresentandfuture